-
A MARKOV MODEL-BASED COST-EFFECTIVENESS ANALYSIS OF ACUPUNCTURE FOR NON-SPECIFIC LOW BACK PAIN IN HONG KONG
Mar 18, 2026, 21:38 PM -
VALIDATION OF AN AGENTIC LARGE LANGUAGE MODEL (LLM) SYSTEM IN THE EXTRACTION STAGE OF A REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEW (REAL-SLR): A SOLUTION TO INSTANT AND EASY ACCESS TO CLINICAL TRIAL DATA (CTD)
Mar 18, 2026, 21:38 PM -
COST ANALYSIS OF LUPUS NEPHRITIS IN THE BRAZILIAN UNIFIED HEALTH SYSTEM - RWD STUDY
Mar 18, 2026, 21:38 PM -
TIMING OF ADJUVANT THERAPY AND TOTAL HEALTHCARE EXPENDITURES FOLLOWING ROBOTIC-ASSISTED LOBECTOMY OF NON-SMALL CELL LUNG CANCER: A SEER-MEDICARE ANALYSIS
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS ANALYSIS OF BIREOCICLIB VERSUS ABEMACICLIB IN HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: COMPARING MATCHING-ADJUSTED INDIRECT COMPARISON AND SIMULATED TREATMENT COMPARISON APPROACHES
Mar 18, 2026, 21:38 PM -
STRATEGIC MARKET ACCESS PLANNING IN BREAST AND LUNG CANCER ENABLED BYREAL-TIMEAI-ASSISTEDLIVINGSYSTEMATICLITERATUREREVIEW (REAL-SLR)SYSTEM
Mar 18, 2026, 21:38 PM -
USE OF A SMALL LANGUAGE MODEL TO IDENTIFY MG-ADL SCORES FROM ENCOUNTER NOTES IN AN EMR SYSTEM
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF NOVEL ANDROGEN RECEPTOR INHIBITORS IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER: A U.S. ANALYSIS INCORPORATING TWO-WAY SENSITIVITY ASSESSMENT
Mar 18, 2026, 21:38 PM -
BUDGET IMPACT ANALYSIS OF OFATUMUMAB FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN MOROCCO: A PROBABILISTIC MULTI-SCENARIO ASSESSMENT FROM THE PUBLIC PAYER PERSPECTIVE
Mar 18, 2026, 21:38 PM -
POST-2020 REAL-WORLD EVIDENCE ON PHARMACOTHERAPIES FOR CHRONIC LYMPHOCYTIC LEUKEMIA: A SCOPING REVIEW
Mar 18, 2026, 21:38 PM -
EXAMINATION OF MOTIVATION FOR AND ABSENCE FROM BREAST CANCER SCREENING
Mar 18, 2026, 21:38 PM -
PATIENT ATTITUDES TO SHARED DECISION-MAKING AND INNOVATIONS IN MUSCLE INVASIVE BLADDER CANCER: A MULTI-COUNTRY FOCUS GROUP
Mar 18, 2026, 21:38 PM -
TRENDS IN SPECIALTY DRUG COVERAGE POLICY COMPLEXITY AMONG US COMMERCIAL HEALTH PLANS
Mar 18, 2026, 21:38 PM -
DEVELOPMENT AND VALIDATION OF A NOMOGRAM TO PREDICT OVERALL SURVIVAL IN NON-SMALL CELL LUNG CANCER
Mar 18, 2026, 21:38 PM -
COST-SAVING OUTCOMES FROM THE IDENTIFICATION AND MANAGEMENT OF PHARMACOLOGICAL INEFFICIENCIES IN PATIENTS WITH CHRONIC DISEASES
Mar 18, 2026, 21:38 PM -
AUTOMATING MODEL PARAMETERISATION FOR HEALTH ECONOMIC MODELS: VALIDATION OF A GEN-AI RAG PIPELINE
Mar 18, 2026, 21:38 PM -
PREDICTING CANCER’S NEXT MOVE AFTER LOCAL/REGIONAL RECURRENCE (LR) FOR HEALTH ECONOMIC EVALUATIONS: A PAN-TUMOR CASE STUDY
Mar 18, 2026, 21:38 PM -
ARTIFICIAL INTELLIGENCE IN PHARMACOECONOMICS AND HEALTH ECONOMICS AND OUTCOME RESEARCH: A REVIEW OF APPLICATIONS AND CHALLENGES
Mar 18, 2026, 21:38 PM -
COST OF ADVERSE EVENT MANAGEMENT IN CHILDREN, ADOLESCENTS, AND ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
BREAKING THE BOTTLENECK: A NOVEL HUMAN+AI PROCESS FOR GENERATING FULLY-ANNOTATED, FOUNDATIONAL-DRAFT PRO MANUSCRIPTS FROM SOURCE MATERIALS IN UNDER 48 HOURS
Mar 18, 2026, 21:38 PM
